Driehaus Capital Management LLC Reduces Holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Driehaus Capital Management LLC trimmed its holdings in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 16.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 613,550 shares of the company’s stock after selling 117,393 shares during the quarter. Driehaus Capital Management LLC’s holdings in Kiniksa Pharmaceuticals were worth $12,136,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Franklin Resources Inc. grew its position in shares of Kiniksa Pharmaceuticals by 1.7% during the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock valued at $1,798,000 after acquiring an additional 1,100 shares during the period. JPMorgan Chase & Co. bought a new stake in Kiniksa Pharmaceuticals during the third quarter valued at about $4,997,000. Nordea Investment Management AB increased its position in Kiniksa Pharmaceuticals by 4.4% in the fourth quarter. Nordea Investment Management AB now owns 194,883 shares of the company’s stock worth $3,818,000 after buying an additional 8,257 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its stake in shares of Kiniksa Pharmaceuticals by 1.9% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 199,525 shares of the company’s stock worth $3,947,000 after buying an additional 3,673 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth about $355,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $26.09 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 1 year low of $17.38 and a 1 year high of $28.56. The firm’s 50 day moving average price is $22.40 and its 200-day moving average price is $21.37. The stock has a market cap of $1.90 billion, a P/E ratio of -186.34 and a beta of 0.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.09. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The company had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. During the same period in the previous year, the firm posted ($0.25) EPS. Kiniksa Pharmaceuticals’s revenue for the quarter was up 72.5% compared to the same quarter last year. As a group, equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. Wedbush reaffirmed an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Finally, Citigroup assumed coverage on Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and a consensus price target of $38.80.

Insider Transactions at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now owns 81,975 shares of the company’s stock, valued at $1,604,250.75. The trade was a 14.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Mark Ragosa sold 36,372 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $22.25, for a total value of $809,277.00. Following the transaction, the chief financial officer now owns 22,958 shares of the company’s stock, valued at $510,815.50. This represents a 61.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 242,768 shares of company stock valued at $5,865,486. 54.57% of the stock is currently owned by insiders.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.